Roundup and Non-Hodgkin Lymphoma (2026): A Comprehensive Evidence-Based Authority Report

By Editorial Team -

Executive Overview

Few environmental health controversies have generated as much scientific, legal, and public debate as the relationship between Roundup (a glyphosate-based herbicide) and Non-Hodgkin lymphoma (NHL).

In 2015, the International Agency for Research on Cancer (IARC) classified glyphosate as “probably carcinogenic to humans.” Regulatory agencies such as the United States Environmental Protection Agency (EPA) and the European Food Safety Authority (EFSA) reached different conclusions. Meanwhile, juries awarded billions in damages against Monsanto, now owned by Bayer.

This report evaluates:

  • The epidemiologic data

  • Regulatory risk assessments

  • Mechanistic toxicology

  • Litigation outcomes

  • Absolute vs relative risk

  • Occupational vs consumer exposure

  • Systems-level environmental carcinogenesis

All major claims below are linked to primary or authoritative sources.

1. What Is Glyphosate and Why Is It So Widely Used?

Glyphosate is the active ingredient in Roundup. Introduced in 1974, it became dominant because:

  • It targets the plant shikimate pathway (absent in humans)

  • It is broad-spectrum

  • It is cost-effective

  • It integrates well with genetically modified crops

After patent expiration in 2000, global production expanded dramatically.

However, Roundup formulations include surfactants and adjuvants. Toxicology studies sometimes show greater biological effects from full formulations than from glyphosate alone.

Stephanie Seneff, Ph.D., a senior research scientist at MIT, published a book, "Toxic Legacy: How the Weedkiller Glyphosate Is Destroying Our Health and the Environment" (Available on Amazon)

2. Understanding Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma (NHL) includes cancers of B-cells, T-cells, and NK cells. Major subtypes include:

  • Diffuse large B-cell lymphoma

  • Follicular lymphoma

  • Mantle cell lymphoma

  • T-cell lymphomas

Known risk factors include:

  • Immunosuppression

  • Autoimmune disorders

  • Viral infections (EBV, HIV)

  • Certain chemical exposures

The incidence rise from the 1970s onward prompted investigation into pesticide exposures.

3. The 2015 IARC Classification

In 2015, IARC classified glyphosate as:

Group 2A — Probably carcinogenic to humans

IARC’s evaluation can be accessed here:
https://www.iarc.who.int/featured-news/media-centre-iarc-news-glyphosate/

What IARC Found

  • Limited evidence in humans (mainly NHL case-control studies)

  • Sufficient evidence in animals

  • Mechanistic evidence (genotoxicity, oxidative stress)

Important: IARC assesses hazard, not exposure-specific risk.

4. Regulatory Agency Risk Assessments

4.1 U.S. EPA

The EPA’s 2020 Interim Registration Review concluded glyphosate is:

“Not likely to be carcinogenic to humans” at labeled exposure levels.

Full EPA human health risk assessment PDF:
https://www.epa.gov/sites/production/files/2016-09/documents/glyphosate_issue_paper_evaluation_of_carcincogenic_potential.pdf

EPA emphasizes:

  • Dose-response modeling

  • Lack of consistent tumor patterns

  • Cohort study evidence

4.2 Europe: EFSA & ECHA

EFSA and ECHA concluded available data do not support classifying glyphosate as carcinogenic under EU regulatory standards.

EFSA assessment overview:
https://www.efsa.europa.eu/en/topics/topic/glyphosate

ECHA classification decision:
https://echa.europa.eu/hot-topics/glyphosate

5. Epidemiologic Evidence: What Do Human Studies Show?

5.1 The 2019 Meta-Analysis

A widely cited meta-analysis found up to a 41% increased risk of NHL in highest exposure groups.

PubMed link:
https://pubmed.ncbi.nlm.nih.gov/31342895/

Full text summary:
https://gmoresearch.org/gmo_article/exposure-to-glyphosate-based-herbicides-and-risk-for-non-hodgkin-lymphoma-a-meta-analysis-and-supporting-evidence/

Key nuance:

  • Association strongest in highest cumulative exposure groups

  • Lower exposure groups showed weaker or no association

  • Relative risk increase ≠ large absolute risk increase

5.2 Updated Review (2025)

A more recent comprehensive review evaluating updated epidemiologic and mechanistic data:

PubMed link:
https://pubmed.ncbi.nlm.nih.gov/41318253/

Earlier foundational review (2021):
https://pubmed.ncbi.nlm.nih.gov/34052177/

These reviews argue that cumulative evidence supports a causal interpretation, particularly in occupational exposure contexts.

5.3 Agricultural Health Study (AHS)

The Agricultural Health Study followed ~54,000 pesticide applicators.

Study homepage:
https://aghealth.nih.gov/

Key findings:

  • No statistically significant association with overall NHL

  • Some suggestive subtype-specific signals

Strengths:

  • Prospective design

  • Reduced recall bias

Criticisms:

  • Exposure misclassification possible

  • Limited power for rare subtypes

6. Mechanistic Evidence

6.1 Oxidative Stress

Laboratory models suggest glyphosate exposure may increase reactive oxygen species, potentially contributing to DNA damage.

6.2 Genotoxicity

Some in vitro assays show DNA strand breaks; however, in vivo replication has been inconsistent.

6.3 Immune Modulation

Because NHL arises from immune cells, immune dysregulation is biologically plausible. Chronic low-grade immune activation is a known carcinogenic driver in lymphomas.

7. Litigation: Scientific vs Legal Standards

Major verdicts include:

Recent example (Associated Press coverage):
https://apnews.com/article/7f903acb350dd6f6ce09b102914eabc1

Juries awarded billions based on:

  • Internal corporate documents

  • Failure-to-warn arguments

  • Expert testimony

Legal causation ≠ scientific consensus.

8. Scientific Integrity Controversies

In 2025, reporting highlighted ethical concerns and retraction issues surrounding certain glyphosate-related publications.

Guardian report:
https://www.theguardian.com/us-news/2025/dec/05/monsanto-roundup-safety-study-retracted

This further fueled public distrust and amplified debate.

9. Absolute vs Relative Risk Explained

If baseline lifetime NHL risk ≈ 2%:

A 40% relative increase → ~2.8% lifetime risk.

For occupational workers, this increase may be meaningful.

For typical consumer exposure, estimated risk increase appears much smaller.

Risk magnitude matters in policy and communication.

10. Occupational vs Consumer Exposure

High-Exposure Groups

  • Licensed pesticide applicators

  • Agricultural workers

  • Groundskeepers

General Population

  • Intermittent residential users

  • Dietary residue exposure within regulatory tolerance

Biomonitoring studies show detectable urinary glyphosate in many populations, but typically at low levels with rapid excretion.

11. Why the Scientific Divide Persists

Several drivers:

  • Hazard vs risk framework differences

  • Formulation vs active ingredient debate

  • Variability in exposure measurement

  • Litigation-driven polarization

  • Institutional trust erosion

This debate reflects broader tensions in environmental health science.

12. Systems-Level Environmental Carcinogenesis

Cancer rarely arises from a single exposure.

Interacting variables include:

  • Chronic inflammation

  • Immune dysregulation

  • Metabolic health

  • Genetic susceptibility

  • Chemical co-exposures

Glyphosate, if causal, likely represents one factor in a multifactorial network.

13. Global Policy Landscape (2026)

Some jurisdictions have:

  • Restricted public use

  • Implemented buffer zones

  • Reassessed registration approvals

However, glyphosate remains widely approved globally.

14. What Would Definitive Proof Require?

To establish causation conclusively:

  • Clear dose-response gradient

  • Consistent subtype-specific association

  • Replicable mechanistic validation

  • Strong temporal consistency

Current evidence remains suggestive but not definitive.

15. Practical Risk Mitigation

Occupational

  • Personal protective equipment

  • Minimize aerosolization

  • Strict adherence to label instructions

  • Consider integrated weed management alternatives

Consumers

  • Wash produce

  • Diversify diet

  • Avoid unnecessary residential spraying

16. Evidence-Weighted Conclusion (2026)

Based on the totality of evidence:

  1. Mechanistic plausibility exists at sufficient exposure levels.

  2. Epidemiologic evidence suggests possible increased NHL risk in heavily exposed occupational groups.

  3. Large cohort studies do not demonstrate a strong overall association.

  4. Regulatory agencies conclude typical exposure levels are unlikely to pose significant cancer risk.

  5. Litigation outcomes reflect jury evaluation of evidence and corporate conduct, not definitive scientific consensus.

Balanced synthesis:

The strongest evidence supports cautious occupational exposure management while not supporting widespread panic regarding consumer-level exposure.

Final Perspective

The Roundup–lymphoma debate represents a case study in:

  • Scientific uncertainty

  • Regulatory philosophy differences

  • Corporate accountability

  • Risk communication challenges

As of 2026:

  • Glyphosate remains widely used

  • Scientific debate continues

  • Regulatory frameworks vary

  • High-exposure contexts warrant careful monitoring

Future clarity will depend on:

  • Updated cohort data

  • Subtype-specific lymphoma research

  • Formulation-specific toxicology

  • Improved cumulative exposure quantification

Until then, the issue remains a dose-dependent probability question — not a binary certainty.

Comments

Post a Comment

Labels

Show more

Archive

Show more

Popular posts from this blog

Ivermectin and Fenbendazole: Treating Turbo Cancer - Dr William Makis

By Editorial Team -
Image
Ivermectin Resources I have seen tremendous demand for some sort of initial guidance “WHERE TO START” with High Dose Ivermectin for CANCER. Editor's Note: Dr Makis proposes four distinct cancer protocols for using Ivermectin in cancer treatment, specifically for patients who have developed turbo cancer or aggressive cancers. These protocols, referred to as the “Dr. Makis Ivermectin Cancer Protocols,” are categorized based on dosage and the severity of the cancer. Updated version I have an article and a video that go into depth: June 10, 2024 - "15 minutes with Dr.Makis" - Episode 018: High Dose Ivermectin and Cancer .  2025 - 2026 studies on ivermectin for cancer Clinical Yuan Yuan et al (Cedars-Sinai Medical Center) - A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer (ASCO 2025) Yuwen et al -  A Review of Ivermectin Use in Cancer Patients: Is it Time to Repurpose t...
Read more

Fenbendazole, Ivermectin and Mebendazole Cancer Success Stories: 567 Case Reports Compilation (February 2026 Edition)

By Editorial Team -
Image
Table of Contents: Editor's Preface Introduction Fenbendazole Case Series Compilation (alphabetical) Breast Cancer Success Stories  (73 cases) Brain Cancer (including Glioblastoma) (116 cases) Bile Duct Cancer (Cholangiocarcinoma)  (4 cases) Bladder Cancer Success Stories  (including kidney cancer) (29 cases) Cervical Cancer  (6 cases) Colorectal Cancer  (including Appendix cancer) (51 cases) Esophageal and Stomach cancer (20 cases) Endometrial Cancer (9 cases) Gastric (Stomach) cancer (see  Esophageal and Stomach Cancer ) (19 cases) Head and Neck Cancer (15 cases) Kidney Cancer Case Series  (including urinary (urothelial) bladder cancer) (27 cases) Liver Cancer (HepatoCellular Cancer)  (3 cases) Lung Cancer (36 cases) Leukemia (9 cases) Lymphoma (20 cases) Melanoma (refer to Skin Cancer ) ...
Read more

Fenbendazole Joe Tippens Protocol: A Step-by-Step Guide (2025)

By Editorial Team -
Image
If you have been diagnosed with cancer, or have a loved one that is suffering from cancer, chances are you have heard about the Joe Tippens Cancer Protocol. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories . We have seen tremendous demand for some sort of guide on how to use fenbendazole for cancer as there is also tremendous confusion both from the healthcare and non-healthcare communities. Joe Tippens founded the protocol (1) after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discovered, through trial and error, a product in their canine product line, fenbendazole, that was batting 1.000 in killing these different cancers in the mice. The scientist was later diagnosed with ...
Read more

Ivermectin, Fenbendazole and Mebendazole Protocol in Cancer: Peer-Reviewed Protocol in Cancer

By Editorial Team -
Image
We are pleased to announce that the first-of-its-kind protocol utilizing Ivermectin, Mebendazole, and Fenbendazole for cancer treatment has been peer-reviewed and officially published on September 19, 2024. Spearheaded by leading researchers like Dr. Ilyes Baghli, Dr. Pierrick Martinez, and the FLCCC’s Dr. Paul Marik, this groundbreaking protocol harnesses the untapped power of Ivermectin, Mebendazole, and Fenbendazole, known for their effectiveness against parasites. Now, these drugs are showing potential to battle cancer, marking the dawn of a new treatment evolution. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. Journal of Orthomolecular Medicine 2024 Targeting the Mitochondri...
Read more

Dr William Makis Ivermectin Protocol 2026 – Complete Guide + Patient Outcomes

By Editorial Team -
Image
Dr. William Makis MD (McGill Medicine, 110+ peer-reviewed publications) runs the world's largest high-dose ivermectin cancer clientele in 2025 – he has guided thousands of patients globally with remarkable results in turbo cancers and conventional failures. This continuously updated 2026 guide compiles Dr. Makis's latest protocols (from his Substack, X posts through 2026, and direct patient correspondence). We cross-reference his exact dosages, schedules, combinations, safety data, sourcing, and real patient outcomes (anonymized but verifiable on his channels). Important Disclaimer: This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician whom you trust to manage your health. Individual results may vary. Do not self-medicate with ivermectin without proper bloodwork and medical monitoring, as misuse can lead to serious side effects and drug interactions. ...
Read more

DMSO 101: Benefits, Uses, Dosage and Side Effects (2026)

By Editorial Team -
Image
In 2022, Erica Eyres, a vigorous fifty-six-year-old aerobics instructor who had struggled to breathe, was given “absolutely devastating” news: She might need a lung transplant. She had never smoked, ran cross-country track in high school, and was a personal trainer for years, but, by 2024, a transplant assessment was arranged. (1) “I decided that I will make that decision,” she said, “only if it’s the last resort, and I’m on my deathbed.” A few months before her consultation, however, Eyres, then fifty-eight, made an appointment with a new primary care doctor for routine prescription refills. She was about to be introduced, literally and figuratively, to a new kind of medicine. It would change everything. DMSO Online Buying Guide (Paid Link) Buy on Amazon Disclosure: OneDayMD.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program that enables sites to earn advertising fees by advertising and linking to Amazon.com, but this is at NO extra co...
Read more

Best Ivermectin Dosage for Humans with Cancer or Different Cancer Types (2026)

By Editorial Team -
Image
Introduction This article discusses dosage considerations and key factors regarding the use of ivermectin in cancer treatment. Commonly available information about ivermectin dosages is often inaccurate when applied to potential cancer-related uses.  Many sources cite standard dosages recommended by Merck for treating parasitic infections, rather than dosages studied specifically in the context of cancer research. The anti-parasitic dosage is not as effective for people looking for a dosage against cancer. Dosage will need to be adjusted according to the  current weight, the type of Cancer, the stage and grade of the Cancer and the health of the liver. Ivermectin dosage should also be based on ivermectin cancer studies. Multiple factors are considered including studies including ivermectin for cancer, anecdotal studies and case series, the aggressiveness of the cancer type and the cancer stage. It also takes into account the types of medications the person uses. For example, i...
Read more

Best Fenbendazole Dosage for Humans: Safety, Side Effects and Efficacy Examined (2026)

By Editorial Team -
Image
Fenbendazole is a broad spectrum anti-parasitic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. (2) Fenbendazole, has garnered ⁤attention​ for its potential use ​in‍ humans.‍ The Fenbendazole Cancer Protocol gained rapid interest over the past years following some fenbendazole advanced cancer success stories  (more than 400 case reports). Joe Tippens founded the protocol  after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different m...
Read more

Fenbendazole and Ivermectin for Prostate Cancer? A Case Series of 64 Patients (February 2026 Edition)

By Editorial Team -
Image
Abstract Background: Advanced prostate cancer, including metastatic hormone-sensitive and castration-resistant forms, often develops resistance to standard androgen deprivation therapies, highlighting the need for novel adjunctive strategies. Repurposed antiparasitic agents such as fenbendazole and ivermectin have garnered attention for their potential anticancer properties, supported by preclinical studies demonstrating microtubule disruption, apoptosis induction, and metastasis inhibition. Methods: This compilation reviews 64 case reports from 2024–2026, sourced from peer-reviewed publications, social media platforms, and personal testimonials. Protocols typically involved fenbendazole (222–2000 mg/day) and ivermectin (1–2 mg/kg/day), often combined with adjuncts li...
Read more

Stage 4 Cancer Remissions with Fenbendazole, Ivermectin and Mebendazole: 318 Case Reports Compilation (February 2026 Edition)

By Editorial Team -
Image
Abstract Background: Stage 4 cancer — defined by metastatic spread beyond the original tumor site — has a poor prognosis with conventional treatment alone. There is growing interest in repurposed antiparasitic drugs such as ivermectin , fenbendazole , and mebendazole for potential antineoplastic effects. Preclinical research suggests mechanisms including disruption of oncogenic signaling pathways and inhibition of cancer cell proliferation and survival, but controlled clinical evidence in humans remains limited. Objective: To summarize and characterize a large compilation of anecdotal clinical case reports describing the use of ivermectin, fenbendazole, and mebendazole in individuals with Stage 4 cancers (various tumor types) and to highlight reported outcomes and therapeutic contexts. Methods: Over 315 individual case reports were aggregated from public sources — predominantly social media posts, practitioner-shared testimonials, and independently published patient narratives....
Read more